Ingi Lee, MD
Infectious Disease · Abington, PANPI 1538213822
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,975 of the $11,999 with a category attached, or 99.8%. Modernatx, Inc. accounts for 99.8% of it on its own, with 1 other manufacturer making up the rest. 2025 is the largest year on record at $10,800, more than ten times the $24 reported in 2023. Among infectious disease clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 6 payments — averaging $1999.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$12K
- Abbott$24
Across 33 payments — averaging $4134.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$136K
What the payments were for
- Consulting fees$11,975100%
- Food & beverage$240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 5 | $11,975 |
| Abbott | 1 | $24 |
How this compares
$11,999 in reported general payments places this provider in the 90th percentile of 457 infectious disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Methenamine Hippurate | 11 | $1,159 |
| Atovaquone-Proguanil HclAtovaquone/Proguanil Hcl | 12 | $967 |
| Azithromycin | 15 | $207 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Abington
- David HornPhiladelphia$2.1M
- Judith WolfPhiladelphia$1.2M
- Karam MounzerPhiladelphia$712K
- William ShortPhiladelphia$520K
- David WuWest Chester$483K
- William PaceSouthampton$472K
- Amesh AdaljaPittsburgh$415K
- Brett GilbertWynnewood$352K
- Timothy BabinchakPhoenixville$311K
- Tuesdae Stainbrookdu Bois$231K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.